ABEO Abeona Therapeutics Inc

Price (delayed)

$1.31

Market cap

$129.71M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.57

Enterprise value

$123.91M

Highlights
ABEO's EPS has soared by 65% year-on-year and by 37% since the previous quarter
Abeona Therapeutics's net income has surged by 51% YoY and by 38% QoQ
Abeona Therapeutics's debt has increased by 10% YoY but it has decreased by 3% QoQ
The company's quick ratio fell by 33% YoY and by 6% QoQ
Abeona Therapeutics's equity has decreased by 29% YoY and by 8% QoQ

Key stats

What are the main financial stats of ABEO
Market
Shares outstanding
99.02M
Market cap
$129.71M
Enterprise value
$123.91M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
1.37
Price to sales (P/S)
12.34
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
12.39
Earnings
Revenue
$10M
EBIT
-$47.14M
EBITDA
-$42.77M
Free cash flow
-$36.67M
Per share
EPS
-$0.57
Free cash flow per share
-$0.39
Book value per share
$0.96
Revenue per share
$0.11
TBVPS
$1.14
Balance sheet
Total assets
$141.43M
Total liabilities
$47.04M
Debt
$8.47M
Equity
$94.39M
Working capital
$47.76M
Liquidity
Debt to equity
0.09
Current ratio
2.17
Quick ratio
2.12
Net debt/EBITDA
0.14
Margins
EBITDA margin
-427.7%
Gross margin
100%
Net margin
-520.8%
Operating margin
-478.1%
Efficiency
Return on assets
-33.8%
Return on equity
-48.1%
Return on invested capital
-61.6%
Return on capital employed
-46.9%
Return on sales
-471.4%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

ABEO stock price

How has the Abeona Therapeutics stock price performed over time
Intraday
-0.76%
1 week
2.34%
1 month
-19.14%
1 year
-55.59%
YTD
-16.56%
QTD
-16.03%

Financial performance

How have Abeona Therapeutics's revenue and profit performed over time
Revenue
$10M
Gross profit
$10M
Operating income
-$47.81M
Net income
-$52.08M
Gross margin
100%
Net margin
-520.8%
The operating income has soared by 55% YoY and by 41% from the previous quarter
Abeona Therapeutics's net income has surged by 51% YoY and by 38% QoQ
ABEO's operating margin is up by 41% QoQ
Abeona Therapeutics's net margin has increased by 38% QoQ

Growth

What is Abeona Therapeutics's growth rate over time

Valuation

What is Abeona Therapeutics stock price valuation
P/E
N/A
P/B
1.37
P/S
12.34
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
12.39
ABEO's EPS has soared by 65% year-on-year and by 37% since the previous quarter
The price to book (P/B) is 51% lower than the 5-year quarterly average of 2.8 and 14% lower than the last 4 quarters average of 1.6
Abeona Therapeutics's equity has decreased by 29% YoY and by 8% QoQ
ABEO's P/S is 96% below its 5-year quarterly average of 286.7

Efficiency

How efficient is Abeona Therapeutics business performance
The company's return on invested capital has surged by 84% YoY and by 39% QoQ
The company's return on assets rose by 44% YoY and by 35% QoQ
Abeona Therapeutics's return on equity has increased by 42% YoY and by 33% QoQ
ABEO's ROS is up by 41% since the previous quarter

Dividends

What is ABEO's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ABEO.

Financial health

How did Abeona Therapeutics financials performed over time
The current ratio has declined by 33% year-on-year and by 7% since the previous quarter
The company's quick ratio fell by 33% YoY and by 6% QoQ
Abeona Therapeutics's debt is 91% lower than its equity
Abeona Therapeutics's debt to equity has surged by 50% YoY
Abeona Therapeutics's equity has decreased by 29% YoY and by 8% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.